TY - JOUR
T1 - Incidence of diabetes according to metabolically healthy or unhealthy normal weight or overweight/obesity in postmenopausal women
T2 - The Women's Health Initiative
AU - Hsu, Amber R.Cordola
AU - Ames, Susan L.
AU - Xie, Bin
AU - Peterson, Darleen V.
AU - Garcia, Lorena
AU - Going, Scott B.
AU - Phillips, Lawrence S.
AU - Manson, Joann E.
AU - Anton-Culver, Hoda
AU - Wong, Nathan D.
N1 - Funding Information:
Received October 5, 2019; revised and accepted December 18, 2019. From the 1School of Community and Global Health, Claremont Graduate University, The Claremont Colleges, Claremont, CA; 2Heart Disease Prevention Program, Division of Cardiology, Department of Medicine, UC Irvine School of Medicine, University of California, Irvine, Irvine, CA; 3Department of Public Health Sciences, Division of Epidemiology, UC Davis School of Medicine, Davis, CA; 4Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ; 5Atlanta VA Medical Center and Division of Endocrinology, Department of Medicine, Emory University, Atlanta, GA; 6Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; and 7Department of Medicine, UC Irvine School of Medicine, University of California, Irvine, Irvine, CA. *Hoda Anton-Culver and Nathan D. Wong are co-senior authors. Abstract accepted/presented at the 2019 American Society for Preventive Cardiology Congress on CVD Prevention Conference in San Antonio, TX. Funding/support: The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. Financial disclosure/conflicts of interest: Dr Lawrence S. Phillips is supported in part by VA awards I01-CX001025, and I01CX001737, NIH awards R21DK099716, U01 DK091958, U01 DK098246, P30DK111024, and R03AI133172, and a Cystic Fibrosis Foundation award PHILLI12A0. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Dr Phillips declares that there is no duality of interest associated with this manuscript. With regard to potential conflicts of interest, within the past several years, Dr Phillips has served on Scientific Advisory Boards for Janssen, and has or had research support from Abbvie, 899ck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, Pfizer, Kowa, and the Cystic Fibrosis Foundation. In the past, he was a speaker for Novartis and Merck, but not for the past 5 years. Dr Phillips is also a cofounder and Officer and Board member and stockholder of a company, DIASYST, Inc., which is developing software aimed to help improve diabetes management. Dr Phillips is also supported in part by the Veterans Health Administration (VA). This work is not intended to reflect the official opinion of the VA or the US government. Dr Nathan Wong has received research support through his institution from Amgen, Amarin, Boehringer-Ingelheim, and Novartis, and is on the speakers bureau for Amarin and Sanofi. The other authors have nothing to disclose.
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Objective:To determine the relationship of metabolic weight categories with incident diabetes mellitus (DM) in postmenopausal women.Methods:The Women's Health Initiative (WHI) enrolled 161,808 postmenopausal women aged 50 to 79 years. We included those with cardiovascular disease (CVD) biomarkers and free of CVD and prevalent DM (n = 17,043) at baseline. Normal weight was defined as a body mass index (BMI) =18.5 and <25 kg/m2, and waist circumference (WC) <88 cm and overweight/obesity as a BMI =25 kg/m2or WC =88 cm. Metabolically healthy was based on <2 and metabolically unhealthy =2 traits of the following: triglycerides =150 mg/dL, systolic blood pressure (BP) =130 mm Hg or diastolic BP =85 mm Hg, or antihypertensives or diuretics, fasting glucose =100 mg/dL or DM medication, and high-density lipoprotein cholesterol <50 mg/dL. Cox regression was performed to determine the risk of incident DM among metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUHNW), metabolically healthy overweight/obese (MHO), and metabolically unhealthy overweight/obese (MUHO).Results:Among our sample, 2,253 (13.3%) participants developed DM over a mean ± standard deviation follow-up time of 15.6 ± 3.4 years. Compared with MHNW (n = 162 incident DM cases), an increased risk of incident DM was observed in MUHNW (n = 102 cases) (hazard ratio [HR] 2.24, 95% confidence interval [CI] 1.74-2.88, P < 0.0001), MHO (n = 624 cases) (HR 1.68, 95% CI 1.40-2.00, P < 0.0001), and MUHO (n = 1,365 cases) (HR 4.51, 95% CI 3.82-5.35, P < 0.0001).Conclusions:Among postmenopausal women, MUHNW and MHO confer an approximate doubling in the risk and MUHO more than a four-fold increased risk for developing DM.
AB - Objective:To determine the relationship of metabolic weight categories with incident diabetes mellitus (DM) in postmenopausal women.Methods:The Women's Health Initiative (WHI) enrolled 161,808 postmenopausal women aged 50 to 79 years. We included those with cardiovascular disease (CVD) biomarkers and free of CVD and prevalent DM (n = 17,043) at baseline. Normal weight was defined as a body mass index (BMI) =18.5 and <25 kg/m2, and waist circumference (WC) <88 cm and overweight/obesity as a BMI =25 kg/m2or WC =88 cm. Metabolically healthy was based on <2 and metabolically unhealthy =2 traits of the following: triglycerides =150 mg/dL, systolic blood pressure (BP) =130 mm Hg or diastolic BP =85 mm Hg, or antihypertensives or diuretics, fasting glucose =100 mg/dL or DM medication, and high-density lipoprotein cholesterol <50 mg/dL. Cox regression was performed to determine the risk of incident DM among metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUHNW), metabolically healthy overweight/obese (MHO), and metabolically unhealthy overweight/obese (MUHO).Results:Among our sample, 2,253 (13.3%) participants developed DM over a mean ± standard deviation follow-up time of 15.6 ± 3.4 years. Compared with MHNW (n = 162 incident DM cases), an increased risk of incident DM was observed in MUHNW (n = 102 cases) (hazard ratio [HR] 2.24, 95% confidence interval [CI] 1.74-2.88, P < 0.0001), MHO (n = 624 cases) (HR 1.68, 95% CI 1.40-2.00, P < 0.0001), and MUHO (n = 1,365 cases) (HR 4.51, 95% CI 3.82-5.35, P < 0.0001).Conclusions:Among postmenopausal women, MUHNW and MHO confer an approximate doubling in the risk and MUHO more than a four-fold increased risk for developing DM.
KW - Cardiometabolic
KW - Diabetes
KW - Obesity
KW - Postmenopausal women
KW - Women's Health Initiative
UR - http://www.scopus.com/inward/record.url?scp=85085631076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085631076&partnerID=8YFLogxK
U2 - 10.1097/GME.0000000000001512
DO - 10.1097/GME.0000000000001512
M3 - Article
C2 - 32108731
AN - SCOPUS:85085631076
SN - 1072-3714
VL - 27
SP - 640
EP - 647
JO - Menopause
JF - Menopause
IS - 6
ER -